Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretroviral treatment-experienced adults, in combination with a boosted protease inhibitor and other antiretrovirals.

Etravirine is the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be launched in 10 years and it is the first NNRTI to show antiviral activity in treatment experienced adult patients resistant to NNRTIs.

Intelence has been authorised under a ‘conditional approval' scheme which means new information on etravirine will be reviewed yearly and the SPC updated as necessary.

View Intelence drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...

Purple, orange, blue and yellow blood test tubes on a tray.

New advice on vitamin B12 monitoring in patients taking metformin

Patients on metformin treatment with risk factors for...